Related Experiment Videos
Haemodynamic and metabolic effects of dazoxiben at rest and during atrial pacing
Insights
Thromboxane B2 (TXB2) significantly increased in arteries during atrial pacing in stable angina patients. Dazoxiben treatment prevented this rise without affecting hemodynamics or myocardial metabolism.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Stable angina pectoris is associated with cardiovascular events.
- Thromboxane B2 (TXB2) plays a role in cardiovascular function and platelet aggregation.
Purpose of the Study:
- To investigate the effect of atrial pacing on Thromboxane B2 (TXB2) levels in patients with stable angina.
- To evaluate the impact of Dazoxiben on arterial TXB2 levels and hemodynamic parameters during pacing.
Main Methods:
- Measurements of TXB2 levels at coronary sinus, pulmonary artery, and femoral artery in 11 stable angina patients.
- Atrial pacing was performed at rest and during drug administration.
- Assessment of systemic, pulmonary, and coronary hemodynamics and myocardial metabolism.
Main Results:
- Arterial TXB2 levels significantly increased by up to 820 pg/ml during atrial pacing.
- No significant changes in TXB2 levels were observed in the pulmonary artery or coronary sinus.
- Oral Dazoxiben (200 mg) abolished the increase in arterial TXB2 without altering hemodynamics or myocardial metabolism.
Conclusions:
- Atrial pacing induces a localized increase in arterial TXB2 in stable angina patients.
- Dazoxiben effectively inhibits this pacing-induced arterial TXB2 surge.
- The findings suggest a potential role for TXA2 inhibition in managing angina-related vascular changes.
Abstract:
1 Thromboxane B2 (TXB2) levels were measured in three sites (coronary sinus, pulmonary artery, and femoral artery) at rest and during atrial pacing in 11 patients with stable angina pectoris. 2 There was a highly significant increase in arterial TXB2 on pacing (by up to 820 pg/ml) but there was no change in the thromboxane levels at the other two sites. 3 Dazoxiben 200 mg orally abolished the increase in arterial TXB2, but had no effect on systemic, pulmonary or coronary haemodynamics, no effect on myocardial metabolism and a variable effect on atrial pacing time to angina.